Results of the Combined Shareholders' General Meeting of June 20, 2024

On June 21, 2024, Inventiva, a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies, revealed the results of its Combined Shareholders' Meeting held on June 20, 2024. Chaired by CEO Frédéric Cren, the meeting took place at Hôtel Castel Burgond in Daix, France.

The meeting's Bureau was constituted with the appointments of Pierre Broqua and Jean Volatier as tellers, and Dorian Raynaldy as secretary. All resolutions presented to the shareholders were adopted, except the 30th resolution, which had a negative recommendation from the Board of Directors. This resolution would have allowed share capital increases reserved for members of a company savings plan.

The compensation policy for corporate officers was approved as per the 2023 Universal Registration Document. The total number of shares with voting rights stood at 52,346,516 out of 52,477,188 shares composing the share capital.